Dare Bioscience GAAP EPS of -$0.18 misses by $0.02

Dare Bioscience reported Q3 GAAP EPS of -$0.18, missing estimates by $0.02. Revenue rose to $48,000 from $2,300 year-over-year, according to the company.

Original reporting
Published Nov 16, 2026, 9:03 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 9:06 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$DARE
Bearish
medium confidence
Mentioned
$DARE
Relevance
8/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$DAREBearishMed
01

Why it matters

A GAAP EPS miss typically pressures near-term sentiment and can affect how traders price future burn rate and milestone-driven value, especially for smaller biotech issuers.

02

Market read

Traders get a fresh earnings datapoint (GAAP EPS miss) plus a reported revenue figure, which can drive immediate repricing of expectations.

03

What to watch

The excerpt lacks guidance, cash balance, and pipeline/clinical catalysts; those could offset the GAAP miss if management framed a clear path to profitability.

Relevance 8/10Novelty 8/10Timing: after-hours/late-day earnings update (published 2026-11-16 21:03:52+00:00)

Background

The piece summarizes Daré Bioscience’s Q3 results from a press release, focusing on GAAP EPS and total revenue for the quarter ended September 30, 2026.

Company-level read

Ticker impact

$DAREBearishMedium confidence
Context

Daré Bioscience reported Q3 GAAP EPS of -$0.18, missing by $0.02, alongside sharply higher reported revenue versus the prior year period.

Expected impact

Likely pressure as traders reprice profitability expectations after the GAAP EPS miss.

Evidence & confidence

The article provides the company’s own Q3 GAAP EPS miss and revenue figures, which are direct inputs to earnings expectations and valuation for a small-cap biotech.

Market effects

Reinforces risk-off sentiment for pre-commercial or loss-making biotech names when GAAP profitability misses.

Limited, company-specific impact likely confined to US small-cap biotech sentiment.

Low, no cross-market policy or macro linkage indicated.

Counterpoint

The revenue comparison appears distorted by a very low prior-year quarter, so the EPS miss may matter more than the headline revenue swing for forward expectations.

Key entities

  • Daré Bioscience, Inc.

    Reported Q3 GAAP EPS of -$0.18 (miss) and total revenue of about $48,000 for the quarter ended September 30, 2026.

Related articles

$DAREMed

Daré Bioscience Reports Third Quarter 2026 Financial Results and Highlights Commercial Execution and Pipeline Advancement

Dare Bioscience, Inc. (DARE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Daré Bioscience Reports Third Quarter 2026 Financial Results and Highlights Commercial Execution and Pipeline Advancement DARE to PLAY™ Sildenafil Cream prescription dispensing activities underway this month, with prescriptions written across 48 states and Washington

$DAREMedAI 8/10

Daré Bioscience to Present Phase 1 Sildenafil Cream Data at Sexual Medicine Society of North America (SMSNA) Annual Fall Scientific Meeting

Daré Bioscience (NASDAQ: DARE) will present Phase 1 data on its Sildenafil Cream at the SMSNA Annual Fall Scientific Meeting. The study showed lower systemic exposure compared to oral sildenafil, with no serious adverse events. The company is developing the cream as a potential treatment for female sexual arousal disorder (FSAD), for which there are currently no FDA-approved treatments.

$DAREMedAI 8/10

Daré Bioscience Reports Phase 1 Sildenafil Cream Data Showing Lower Systemic Exposure

Daré Bioscience (DARE) reported Phase 1 data for its Sildenafil Cream, showing lower systemic exposure than oral sildenafil. The study, published in Sexual Medicine, involved 62 healthy men and found significantly lower plasma concentrations for topical administration. The cream is being developed for women's sexual health. DARE stock is currently trading at $0.71, up 0.69%.

$DAREMed

Daré Bioscience Reports Second Quarter 2026 Results and Highlights Commercial Inflection as Multi-Product Women’s Health Strategy Advances

Dare Bioscience, Inc. (DARE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Daré Bioscience Reports Second Quarter 2026 Results and Highlights Commercial Inflection as Multi-Product Women’s Health Strategy Advances Company launches Flora Sync LF5™, the company’s first directly commercialized product, began generating revenue in July DARE to